European Society for Radiotherapy and Oncology (ESTRO) shared a post on LinkedIn:
“Breast cancer radiotherapy is evolving fast, and ESTRO26 delivered a wealth of new evidence to guide practice.
From ultra-hypofractionation and PBI, to oligometastatic SBRT, proton therapy, and the growing interplay between radiotherapy and the immune system, this year’s congress covered it all.
The ESTRO breast focus group has put together a detailed report summarising the highlights, including:
- Long-term results from EORTC 22922 and DBCG IMN2 on nodal irradiation:
- New data on treatment de-escalation in low-risk patients
- Updates on technological innovations including particle therapy and brachytherapy
- Emerging insights on radiotherapy and immune response
Whether you’re a clinician, researcher, or trainee in radiation oncology, this is essential reading.”